Standard

Профиль метилирования генов при онкогематологических заболеваниях. / Mikhaleva, Mariia Andreevna; Zherniakova, A. A.; Krysiuk, O. B.; Sidorkevich, S. V.

In: КЛИНИЧЕСКАЯ ОНКОГЕМАТОЛОГИЯ. ФУНДАМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ И КЛИНИЧЕСКАЯ ПРАКТИКА, Vol. 19, No. 1, 2026, p. 27-38.

Research output: Contribution to journal › Article › peer-review

Harvard

Mikhaleva, MA, Zherniakova, AA, Krysiuk, OB & Sidorkevich, SV 2026, 'Профиль метилирования генов при онкогематологических заболеваниях', КЛИНИЧЕСКАЯ ОНКОГЕМАТОЛОГИЯ. ФУНДАМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ И КЛИНИЧЕСКАЯ ПРАКТИКА, vol. 19, no. 1, pp. 27-38. https://doi.org/10.21320/2500-2139-2026-19-1-27-38

APA

Mikhaleva, M. A., Zherniakova, A. A., Krysiuk, O. B., & Sidorkevich, S. V. (2026). Профиль метилирования генов при онкогематологических заболеваниях. КЛИНИЧЕСКАЯ ОНКОГЕМАТОЛОГИЯ. ФУНДАМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ И КЛИНИЧЕСКАЯ ПРАКТИКА, 19(1), 27-38. https://doi.org/10.21320/2500-2139-2026-19-1-27-38

Vancouver

Mikhaleva MA, Zherniakova AA, Krysiuk OB, Sidorkevich SV. Профиль метилирования генов при онкогематологических заболеваниях. КЛИНИЧЕСКАЯ ОНКОГЕМАТОЛОГИЯ. ФУНДАМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ И КЛИНИЧЕСКАЯ ПРАКТИКА. 2026;19(1):27-38. https://doi.org/10.21320/2500-2139-2026-19-1-27-38

Author

Mikhaleva, Mariia Andreevna ; Zherniakova, A. A. ; Krysiuk, O. B. ; Sidorkevich, S. V. / Профиль метилирования генов при онкогематологических заболеваниях. In: КЛИНИЧЕСКАЯ ОНКОГЕМАТОЛОГИЯ. ФУНДАМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ И КЛИНИЧЕСКАЯ ПРАКТИКА. 2026 ; Vol. 19, No. 1. pp. 27-38.

BibTeX

@article{1d492364e0794c2bb4685280d775682f,
title = "Профиль метилирования генов при онкогематологических заболеваниях",
abstract = "Hematologic malignancies are characterized by a pronounced heterogeneity of tumor clone accounted for by both gene abnormalities and epigenetic changes including abnormal DNA methylation as well as impaired regulation of histone modifications and non-coding RNAs. Recent developments in high-throughput sequencing technology confirmed the key role of epigenetic modifications in the regulation of dynamic biological processes. Over the past years, a considerable body of knowledge has been generated to document the effect of changing epigenetic mechanisms on the development and further progression of hematologic tumors. The analysis of methylation profile leads to detecting the unique epigenetic signatures correlating with clinical outcomes and refractoriness to chemotherapy. This review systematizes current views on the role of DNA methylation in oncohematology and various methods of its analysis as well as the outlook for the therapy targeting the epigenetic abnormalities.",
keywords = "DNA methylation, bisulfite conversion, epigenetics, hematologic malignancies",
author = "Mikhaleva, {Mariia Andreevna} and Zherniakova, {A. A.} and Krysiuk, {O. B.} and Sidorkevich, {S. V.}",
year = "2026",
doi = "10.21320/2500-2139-2026-19-1-27-38",
language = "русский",
volume = "19",
pages = "27--38",
journal = "Klinicheskaya Onkogematologiya/Clinical Oncohematology",
issn = "1997-6933",
publisher = "ПРАКТИЧЕСКАЯ МЕДИЦИНА",
number = "1",

}

RIS

TY - JOUR

T1 - Профиль метилирования генов при онкогематологических заболеваниях

AU - Mikhaleva, Mariia Andreevna

AU - Zherniakova, A. A.

AU - Krysiuk, O. B.

AU - Sidorkevich, S. V.

PY - 2026

Y1 - 2026

N2 - Hematologic malignancies are characterized by a pronounced heterogeneity of tumor clone accounted for by both gene abnormalities and epigenetic changes including abnormal DNA methylation as well as impaired regulation of histone modifications and non-coding RNAs. Recent developments in high-throughput sequencing technology confirmed the key role of epigenetic modifications in the regulation of dynamic biological processes. Over the past years, a considerable body of knowledge has been generated to document the effect of changing epigenetic mechanisms on the development and further progression of hematologic tumors. The analysis of methylation profile leads to detecting the unique epigenetic signatures correlating with clinical outcomes and refractoriness to chemotherapy. This review systematizes current views on the role of DNA methylation in oncohematology and various methods of its analysis as well as the outlook for the therapy targeting the epigenetic abnormalities.

AB - Hematologic malignancies are characterized by a pronounced heterogeneity of tumor clone accounted for by both gene abnormalities and epigenetic changes including abnormal DNA methylation as well as impaired regulation of histone modifications and non-coding RNAs. Recent developments in high-throughput sequencing technology confirmed the key role of epigenetic modifications in the regulation of dynamic biological processes. Over the past years, a considerable body of knowledge has been generated to document the effect of changing epigenetic mechanisms on the development and further progression of hematologic tumors. The analysis of methylation profile leads to detecting the unique epigenetic signatures correlating with clinical outcomes and refractoriness to chemotherapy. This review systematizes current views on the role of DNA methylation in oncohematology and various methods of its analysis as well as the outlook for the therapy targeting the epigenetic abnormalities.

KW - DNA methylation

KW - bisulfite conversion

KW - epigenetics

KW - hematologic malignancies

UR - https://www.mendeley.com/catalogue/ecd07e65-adab-3727-b75c-713c8af6def6/

U2 - 10.21320/2500-2139-2026-19-1-27-38

DO - 10.21320/2500-2139-2026-19-1-27-38

M3 - статья

VL - 19

SP - 27

EP - 38

JO - Klinicheskaya Onkogematologiya/Clinical Oncohematology

JF - Klinicheskaya Onkogematologiya/Clinical Oncohematology

SN - 1997-6933

IS - 1

ER -

ID: 149276848